Orphan diseases Market information, by Type of Diseases (autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders), Type of Treatment (gene therapy, cell therapy, drug therapy , End user (hospital and clinics, research laboratory) -Forecast to 2032

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Mega Trends

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5 Market Factor Analysis

5.1 Value/Supply Chain Analysis

5.2 Porter's 5 Forces Analysis

5.3 Pricing Analysis

5.4 Investment Opportunity Analysis

5.5 Merger and Acquisition Landscape

6 Global Orphan diseases Market Market, By Disease Type (USD Million)

6.1 Introduction

6.2 Market Size By Disease Type

6.2.1 Autoimmune Disorders

6.2.2 Genetic Disorders

6.2.3 Blood Disorders

6.2.4 Cancer

6.2.5 Growth Disorder

6.2.6 Cardiovascular Diseases

6.2.7 Neurological Disorders

6.2.8 Respiratory Disorders

6.2.8 Digestive Disorders

6.2.9 Eye Disorders

6.2.10 Others

7 Global Chronic Disease Management Market, By Treatment Type (USD Million)

7.1 Introduction

7.2 Market Size By Treatment Type

7.2.1 Gene Therapy

7.2.2 Drug Therapy

7.2.3 Drug Therapy

7.2.4 Others

8 Global Chronic Disease Management Market, By End User (USD Million)

8.1 Introduction

8.2 Market Size By End User

8.2.1 Hospitals and Clinics

8.1.2 Research Laboratories

8.1.3 Others

9 Global Orphan Disease Market, By Region (USD Million)

9.1 Introduction

9.2 Market Size By Region

9.3 Market Size By Region

9.3.1 North America

9.3.1.1 The U.S.

9.3.1.2 Canada

9.3.2 Latin America

9.3.3 Europe

9.3.3.1 Western Europe

9.3.3.1.1 Germany

9.3.3.1.2 France

9.3.3.1.3 Italy

9.3.3.1.4 Spain

9.3.3.1.5 UK

9.3.3.2 Eastern Europe

9.3.4 Asia-Pacific

9.3.4.1 Asia

9.3.4.1.1 Japan

9.3.4.1.2 China

9.3.4.1.3 India

9.3.4.1.4 Australia

9.3.4.1.5 Republic of Korea

9.3.4.2 Rest of Asia-Pacific

9.3.5 Middle East & Africa

10 Company Landscape

10.1 Introduction: Key Players

10.2 Market Share Analysis

10.3 Key Development & Strategies

11 Company Profiles

11.1 Bristol-Myers Squibb Company

11.1.1 Company Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Novartis AG

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financials

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 CELGENE CORPORATION

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financials

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.4 F. Hoffmann-La Roche Ltd

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financials

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.5 Pfizer Inc.

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financials

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Alexion

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financials

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Sanofi

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Vertex Pharmaceuticals Incorporated

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financials

118.4 Key Developments

11.8.5 SWOT Analysis

11.9 GlaxoSmithKline plc.

11.9.1 Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Merck & Co., Inc

11.10.1 Overview

11.10.2 Product/Business Segment Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 AbbVie Inc.

11.11.1 Overview

11.11.2 Product/Business Segment Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

List of Tables

TABLE 1 GLOBAL ORPHAN DISEASE MARKET, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL ORPHAN DISEASE MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TRATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE

FIGURE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TREATMENT TYPE

FIGURE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER

FIGURE 6 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION

FIGURE 7 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)